Stockreport

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker –– Positive interim topline data for [Read more]